Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting cell-intrinsic metabolism for antifibrotic therapy
Hélène Gilgenkrantz, Ariane Mallat, Richard Moreau, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1442-1454
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 322
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
Metabolic reprogramming in liver fibrosis
Paul Horn, Frank Tacke
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1439-1455
Open Access | Times Cited: 67
XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progression
Qi Wang, Qingfa Bu, Mu Liu, et al.
JHEP Reports (2022) Vol. 4, Iss. 11, pp. 100555-100555
Open Access | Times Cited: 60
New Drugs for Hepatic Fibrosis
Liang Shan, Fengling Wang, Dandan Zhai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 46
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming
Morgane Mabire, Pushpa Hegde, Adel Hammoutène, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 40
Albumin, an interesting and functionally diverse protein, varies from ‘native’ to ‘effective’ (Review)
Nijin Wu, Tiantian Liu, Miaomiao Tian, et al.
Molecular Medicine Reports (2023) Vol. 29, Iss. 2
Open Access | Times Cited: 33
Mechanisms of Targeted Drug Delivery for Liver Cancer: Active, Passive, and Subcellular Strategies
Tian Yang, Yu-Sheng Shi
Journal of Biosciences and Medicines (2025) Vol. 13, Iss. 02, pp. 369-384
Open Access | Times Cited: 1
Metabolic Reprogramming of Liver Fibrosis
M. Eugenia Delgado, Beatriz Cárdenas, Núria Farran, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3604-3604
Open Access | Times Cited: 45
Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy
Huiyan Sun, Dandan Chen, Wenjing Xin, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Simona Cernea
Life (2024) Vol. 14, Iss. 2, pp. 272-272
Open Access | Times Cited: 8
Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis
Moris Sangineto, Martina Ciarnelli, Tommaso Colangelo, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101564-101564
Open Access | Times Cited: 7
Kinsenoside Alleviates Alcoholic Liver Injury by Reducing Oxidative Stress, Inhibiting Endoplasmic Reticulum Stress, and Regulating AMPK-Dependent Autophagy
Limin Gao, Xingyu Chen, Zeyu Fu, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 24
Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis
Le Li, Zhijun Zhu
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 14
Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis
Tobias Puengel, Frank Tacke
Liver International (2024) Vol. 44, Iss. 2, pp. 275-278
Closed Access | Times Cited: 5
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 515-538
Open Access | Times Cited: 5
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Shalil Khanal, Yuanhang Liu, Adebowale O. Bamidele, et al.
Science Advances (2024) Vol. 10, Iss. 26
Open Access | Times Cited: 5
The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression
Fenfen Li, Zhaoxia Cheng, Jingyi Sun, et al.
Nano Letters (2023) Vol. 23, Iss. 10, pp. 4126-4135
Closed Access | Times Cited: 12
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Neda Shakour, Shima Karami, Mehrdad Iranshahi, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 18, Iss. 1, pp. 102934-102934
Closed Access | Times Cited: 12
Deletion of GPR81 activates CREB/Smad7 pathway and alleviates liver fibrosis in mice
Ying Zhi, Kerui Fan, Shuang Liu, et al.
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 4
PKMζ: A Brain Kinase Driving Metabolic Reprogramming and Myofibroblastic Differentiation
Aveline Filliol
Cellular and Molecular Gastroenterology and Hepatology (2025), pp. 101437-101437
Open Access
Defective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation
Rola Al Sayegh, Jinghong Wan, Charles Caër, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
O-GlcNAcylation controls pro-fibrotic transcriptional regulatory signaling in myofibroblasts
Ninon Very, Clémence Boulet, Céline Gheeraert, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 3
Hepatoprotective effects of vildagliptin mitigates lung biochemical and histopathological changes in experimental hepatopulmonary syndrome model in rat
Safwat A. Mangoura, Marwa A Ahmed, Nashwa Hamad, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113254-113254
Closed Access | Times Cited: 3
Inhibition of HSC proliferation and hepatic fibrogenesis with Erythrocyte membrane coated Doxorubicin/Black phosphorus nanosheets
Xiang Li, Xianjing Xiang, Qiangqiang Jiao, et al.
International Journal of Pharmaceutics (2025) Vol. 673, pp. 125403-125403
Closed Access
Page 1 - Next Page

Scroll to top